TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05439577
Drug: Mucopolysaccharide Polysulfate Cream
Normalized name: mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using Hirudoid® alone
Study: NCT05439577
Drug: Mucopolysaccharide Polysulfate Cream and glucocorticoids
Normalized name: mucopolysaccharide polysulfate
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
Study: NCT06312982
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
Study: NCT00004736
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004736
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004736
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05476991
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
Study: NCT05476991
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
Study: NCT05476991
Drug: Aspirin 75-300mg
Normalized name: aspirin 300 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
Study: NCT04686682
Drug: JAB-8263
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dose, orally Q2D with 28 days each cycle
Study: NCT04686682
Drug: JAB-8263
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP2D dose, orally Q2D with 28 days each cycle
Study: NCT05974683
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Study: NCT06141304
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
Study: NCT04851860
Drug: sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
Study: NCT00000942
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05638347
Drug: HRS-7085 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT02204553
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treating patients with relapsed and/or refractory Multiple Myeloma
Study: NCT06485336
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet will be taken once daily for 84 days.
Study: NCT05245591
Drug: Pentosan Polysulfate Sodium 100 MG Oral Capsule
Normalized name: Pentosan polysulfate sodium 100 mg oral capsule
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
Study: NCT06035614
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus monohydrate ointment 0.1% TACRUS
Study: NCT04866862
Drug: Combination of Fruquintinib and Camrelizumab
Normalized name: combinations of levothyroxine and liothyronine
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
Study: NCT04674774
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
Study: NCT04674774
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
Study: NCT00257114
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06282211
Drug: Ondansetron Oral Soluble Pellicles
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.
Study: NCT05205109
Drug: ATG-037
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1.
Study: NCT05606315
Drug: Remimazolam Besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
Study: NCT05606315
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
Study: NCT05606315
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
Study: NCT05203705
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, for 12 days
Study: NCT06171555
Drug: Celestone
Normalized name: Celestone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard of care
Study: NCT04864366
Drug: Tenofovir Alafenamide 25 MG [Vemlidy]
Normalized name: tenofovir alafenamide 25 MG [Vemlidy]
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
Study: NCT04831047
Drug: Oxymetazoline hydrochloride 0.1% ophthalmic solution
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
Study: NCT05241561
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile.
Study: NCT05828225
Drug: CD19 CAR-T cells injection
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
Study: NCT05645289
Drug: Minodronate
Normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
Study: NCT05257447
Drug: Baclofen 20 mg Tablet
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
Study: NCT05257447
Drug: Chlorzoxazone 500 mg Tablet
Normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
Study: NCT05257447
Drug: Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet
Normalized name: baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
Study: NCT05645289
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
Study: NCT04867785
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered SC
Study: NCT05721573
Drug: ABC008
Normalized name: Immunoglobulin G1, anti-(human killer cell lectin-like receptor subfamily G member 1) (human-Mus musculus monoclonal ABC008 γ1-chain), disulfide with human-Mus musculus monoclonal ABC008 κ-chain, dime
DrugBank: Ulviprubart (DB18281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by subcutaneous injection
Study: NCT06289790
Drug: Lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine bolus and infusion for pain management in VATS procedure
Study: NCT04585490
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
Study: NCT04585490
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
Study: NCT04585490
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/m2 on Day 1 of every 21-day cycle
Study: NCT04585490
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175mg/m2 on Day 1 of every 21-day cycle
Study: NCT04585490
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
Study: NCT04585490
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: not to exceed 75mg IV on Day 1 of every 21-day cycle
Study: NCT05678283
Drug: CC-90010
Normalized name: Bet inhibitor cc-90010
DrugBank: Trotabresib (DB17421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05730738
Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release
Normalized name: Dalfampridine ER, 10 mg oral tablet, extended release
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
Study: NCT05097118
Drug: Ketamine Versus Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs Ketamine versus Bupivacaine
Study: NCT05197257
Drug: Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
Study: NCT05864677
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
Study: NCT05461105
Drug: rencofilstat, 75 mg
DrugBank: Rencofilstat (DB18246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 softgel capsule
Study: NCT05461105
Drug: rencofilstat, 150mg
DrugBank: Rencofilstat (DB18246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 softgel capsules
Study: NCT05461105
Drug: rencofilstat, 225 mg
DrugBank: Rencofilstat (DB18246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 softgel capsules
Study: NCT05266105
Drug: Palazestrant
Normalized name: Palazestrant
DrugBank: Palazestrant (DB18971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Estrogen Receptor Antagonist
Study: NCT05266105
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib is an approved CDK 4/6 Inhibitor drug
Study: NCT06359600
Drug: HS-10501 tablet
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05999149
Drug: Camrelizumab Plus Chemotherapy and Famitinib
Normalized name: Camrelizumab
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
Study: NCT05999149
Drug: Camrelizumab Plus Chemotherapy
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab Plus Chemotherapy
Study: NCT05681273
Drug: Chiglitazar
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 48mg
Study: NCT05681273
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg
Study: NCT05681273
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg
Study: NCT05681273
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160mg
Study: NCT01418612
Drug: Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04444843
Drug: Mycophenolate Mofetil Capsules
Normalized name: Mycophenolate Mofetil Capsules
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
Study: NCT05006326
Drug: 68Ga-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
Study: NCT05653271
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting agent
Study: NCT05653271
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD20 monoclonal antibody
Study: NCT04744181
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
Study: NCT05891145
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
Study: NCT05891145
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
Study: NCT05597800
Drug: Nivolumab and Ipilimumab
Normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles).
Study: NCT06258213
Drug: ABP-745
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5, 5 or 25 mg tablet
Study: NCT05656443
Drug: GST-HG171/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose of 150 mg GST-HG171 with 100 mg ritonavir
Study: NCT06174935
Drug: 0.01% atropine ophthalmic drop
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% atropine ophthalmic drop will be applied daily to the affected eye
Study: NCT06370442
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal dexmedetomidine, 100mcg
Study: NCT06370442
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg IV
Study: NCT06370442
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg IV
Study: NCT05852145
Drug: Stevioside
Normalized name: Stevioside
DrugBank: Stevioside (DB16882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~* Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later.
Study: NCT05329168
Drug: Tonabacase (LSVT-1701)
Normalized name: Tonabacase
DrugBank: Tonabacase (DB17964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 or 6.0 mg/kg IV once daily for 4 days
Study: NCT04855045
Drug: sepofarsen
Normalized name: Sepofarsen
DrugBank: Sepofarsen (DB16327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA antisense oligonucleotide for intravitreal injection
Study: NCT04970719
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
Study: NCT04970719
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course